Which practice best supports metabolic monitoring in patients with schizophrenia on antipsychotic medications?

• A. Rely on patient self-report only
• B. Ignore metabolic risks during treatment
• C. Cross-disciplinary coordination and regular metabolic monitoring
• D. Schedule metabolic monitoring only if symptoms arise

Answer: (C)

Metabolic monitoring is essential for patients with schizophrenia on antipsychotic medications because these drugs commonly cause weight gain, insulin resistance, dyslipidemia, and elevated blood pressure, which together raise cardiovascular risk. The best practice is cross-disciplinary coordination with a structured, ongoing monitoring plan. This means a team approach—psychiatry, primary care, nutrition or dietetics, and nursing—doing baseline assessments before starting therapy and regular follow-ups thereafter. Track objective factors such as weight and body mass index, waist circumference, blood pressure, fasting glucose or HbA1c, and lipid panels, along with lifestyle factors like diet, activity, and smoking. Shared documentation and communication among all providers enable timely interventions, including lifestyle counseling, medical management of metabolic abnormalities, and adjustments to antipsychotic treatment if needed. Relying on patient self-report alone misses subtle changes, ignoring metabolic risks delays detection, and monitoring only when symptoms appear allows harm to develop before action is taken.